Moderna's Cancer Vaccine Breakthrough Leaves Wall Street Wrestling With a $500,000 Question

Moderna's personalized mRNA cancer vaccine cuts melanoma relapse risk, shares surge 163% in a month, but analysts warn valuation is stretched.

The word "monumental" doesn't get thrown around lightly in oncology circles. When ASCO's Julie Gralow used it to describe the Phase 3 results of Moderna's personalized mRNA cancer vaccine, intismeran autogene, she captured something bigger than a single trial win. The data, unveiled alongside partner Merck, showed the therapy — combined with pembrolizumab (Keytruda) — cut relapse risk substantially in high-risk melanoma patients across a study of more than 1,000 participants.

The market's response was characteristically chaotic. Moderna shares spiked as much as 177 percent before giving back roughly 22 percent of that gain. The stock now trades at 127.96 euros, up 163 percent over the past month and 382 percent since the start of the year. It sits about 14 percent below its 52-week high of 149.62 euros, which was touched only recently.

Those figures belong to a different asset class entirely — the kind of numbers usually reserved for crypto or AI darlings, not an established biopharma name. And they've created a peculiar standoff: the rally has been so ferocious that even the analysts most willing to revise their models admit the stock has run ahead of itself.

The Skeptics Concede — But Only So Far

Wolfe Research's shift this week captures the tension perfectly. The firm, one of Moderna's most persistent bears, upgraded its rating from "Underperform" to "Peer Perform" — a grudging acknowledgment that the risk-reward profile has fundamentally changed since the INTerpath-001 study hit its primary endpoint on recurrence-free survival. Wolfe now pencils in peak sales of $9.2 billion for intismeran across four oncology indications.

Yet the firm stopped short of a buy rating. That restraint speaks volumes about where the debate currently sits. JPMorgan, for its part, dramatically raised its price target while maintaining an "Underweight" stance, arguing the melanoma trial's success is already priced in. Barclays, meanwhile, lifted its target from $48 to $125.

The analyst target range still sits meaningfully below where the market is trading — a gap that triggered a 5.6 percent pullback on Wednesday as traders took profits. Even so, the stock managed to add 13 percent over the past seven days, evidence that the post-trial euphoria hasn't dissipated so much as paused for breath.

A Platform Story That Extends Beyond COVID

What makes this moment feel different from Moderna's pandemic-era run is the breadth of the platform validation. The FDA's recent approval of mFLUSIVA, the first mRNA-based flu vaccine for adults 50 and older, contributed to a 133.4 percent share gain over the past two weeks alone. Combined with the melanoma data, the message is clear: mRNA technology isn't a one-disease wonder.

The commercial potential is staggering. GlobalData counts more than 112,000 melanoma diagnoses annually in the US alone, roughly a third of them high-risk cases. Revenue from this single indication is projected to exceed $1 billion by 2031. Reports suggest a course of the personalized vaccine could carry a price tag around $500,000 — a figure that underscores how far healthcare economics have shifted toward individualized, high-cost therapies.

Competitors are circling the same opportunity. CG Oncology is advancing its oncolytic platform, and Akeso just posted its own successful Phase 3 result against an AstraZeneca product. The field is nowhere near settled.

The Valuation Conundrum

The uncomfortable question hanging over Moderna's rally is how much clinical future the current price already anticipates. An FDA approval for the US market isn't considered realistic before 2027 at the earliest. Between now and then lie regulatory hurdles, pricing negotiations, and manufacturing and commercialization risks that industry publications are quick to flag.

Insider activity adds another wrinkle. CEO Stéphane Bancel and President Stephen Hoge have both sold shares in recent weeks through pre-arranged trading plans — timed, notably, during a period of sharp appreciation. On the flip side, BlackRock built a new position of roughly $2.14 billion in the second quarter, a counterweight suggesting institutional investors remain committed to the long-term thesis despite the volatility.

What's striking is how this story has decoupled from the broader market narrative. While US benchmarks wobbled Wednesday on softer-than-expected PCE inflation data, Moderna marched to its own drummer — driven not by interest rate expectations but by laboratory results. In a week dominated by AI mega-rounds and Nvidia's record revenue, the biotech sector reminded investors it can still generate headlines without a single mention of artificial intelligence.

What Happens Next

The full melanoma dataset lands at the ESMO congress in Madrid at the end of October. That's when the market will learn whether current valuation levels are justified by hard numbers or whether the recent correction marks the beginning of a longer consolidation.

For now, the Wolfe upgrade reads less as a buy signal and more as confirmation that the debate has shifted — from whether intismeran works to how profitable it will ultimately be. That's progress, of a sort. But for a stock trading at levels that would make a crypto enthusiast blush, the margin for disappointment remains razor-thin. The next few months will determine whether Moderna's mRNA oncology bet becomes the platform story of the decade or a cautionary tale about how far enthusiasm can outrun evidence.